No Residual Basal Cell Carcinoma after Excision for Biopsy-proven Tumor: Clinical and Medicolegal Implications

Summary: Our analysis of 127 head and neck region basal cell carcinomas (BCCs) showed that there was no evidence of residual BCC in 15% of patients, one of which is presented in this report. These patients received some type of reconstructive surgery after excision of lesions with negative tumor. Th...

Full description

Bibliographic Details
Main Authors: Raffi Gurunluoglu, MD, PhD, FACS, Eddie Kubek, MD, Jamie Arton, PA-C, Adam Olsen, DDS, Michael Bronsert, PhD, MS
Format: Article
Language:English
Published: Wolters Kluwer 2013-12-01
Series:Plastic and Reconstructive Surgery, Global Open
Online Access:http://journals.lww.com/prsgo/Fulltext/2013/12000/Article.5.aspx
_version_ 1811203930012516352
author Raffi Gurunluoglu, MD, PhD, FACS
Eddie Kubek, MD
Jamie Arton, PA-C
Adam Olsen, DDS
Michael Bronsert, PhD, MS
author_facet Raffi Gurunluoglu, MD, PhD, FACS
Eddie Kubek, MD
Jamie Arton, PA-C
Adam Olsen, DDS
Michael Bronsert, PhD, MS
author_sort Raffi Gurunluoglu, MD, PhD, FACS
collection DOAJ
description Summary: Our analysis of 127 head and neck region basal cell carcinomas (BCCs) showed that there was no evidence of residual BCC in 15% of patients, one of which is presented in this report. These patients received some type of reconstructive surgery after excision of lesions with negative tumor. Thus, there is a chance that any reexcision after a shave biopsy which is positive for BCC may be negative for tumor. This finding substantiates our realization that sometimes what some would call unnecessary surgery is a common reality. The surgeon’s goal is tumor eradication, and therefore, watchful waiting is usually not a legitimate clinical implication. This report has value in letting our esteemed legal colleagues know what we do not know, which still remains within the standard of appropriate care. However, the finding of no residual tumor in the current report may change our practice habits. Watchful waiting may be an option, particularly in the elderly and fragile patients. Also, one may opt to decrease the safety margins during excision when treating patients with biopsy-proven BCC. However, reconstructive procedures may still be required in the case of nonpersistent tumor. Therefore, it is extremely important that the informed consent should include statements regarding possible reconstructive procedures to avoid medicolegal implications.
first_indexed 2024-04-12T03:03:06Z
format Article
id doaj.art-b9b1e752defb48bc8ce17e4ca3527564
institution Directory Open Access Journal
issn 2169-7574
language English
last_indexed 2024-04-12T03:03:06Z
publishDate 2013-12-01
publisher Wolters Kluwer
record_format Article
series Plastic and Reconstructive Surgery, Global Open
spelling doaj.art-b9b1e752defb48bc8ce17e4ca35275642022-12-22T03:50:36ZengWolters KluwerPlastic and Reconstructive Surgery, Global Open2169-75742013-12-0119e8710.1097/GOX.000000000000002701720096-201312000-00005No Residual Basal Cell Carcinoma after Excision for Biopsy-proven Tumor: Clinical and Medicolegal ImplicationsRaffi Gurunluoglu, MD, PhD, FACS0Eddie Kubek, MD1Jamie Arton, PA-C2Adam Olsen, DDS3Michael Bronsert, PhD, MS4From the Department of Plastic and Reconstructive Surgery, Denver Health Medical Center, Denver, Colo.From the Department of Plastic and Reconstructive Surgery, Denver Health Medical Center, Denver, Colo.From the Department of Plastic and Reconstructive Surgery, Denver Health Medical Center, Denver, Colo.Department of Oral Maxillofacial Surgery, Denver Health Medical Center, Denver, Colo.;Department of Biostatistics, Colorado Health Outcomes Program (COHO), University of Colorado, Aurora, Colo.Summary: Our analysis of 127 head and neck region basal cell carcinomas (BCCs) showed that there was no evidence of residual BCC in 15% of patients, one of which is presented in this report. These patients received some type of reconstructive surgery after excision of lesions with negative tumor. Thus, there is a chance that any reexcision after a shave biopsy which is positive for BCC may be negative for tumor. This finding substantiates our realization that sometimes what some would call unnecessary surgery is a common reality. The surgeon’s goal is tumor eradication, and therefore, watchful waiting is usually not a legitimate clinical implication. This report has value in letting our esteemed legal colleagues know what we do not know, which still remains within the standard of appropriate care. However, the finding of no residual tumor in the current report may change our practice habits. Watchful waiting may be an option, particularly in the elderly and fragile patients. Also, one may opt to decrease the safety margins during excision when treating patients with biopsy-proven BCC. However, reconstructive procedures may still be required in the case of nonpersistent tumor. Therefore, it is extremely important that the informed consent should include statements regarding possible reconstructive procedures to avoid medicolegal implications.http://journals.lww.com/prsgo/Fulltext/2013/12000/Article.5.aspx
spellingShingle Raffi Gurunluoglu, MD, PhD, FACS
Eddie Kubek, MD
Jamie Arton, PA-C
Adam Olsen, DDS
Michael Bronsert, PhD, MS
No Residual Basal Cell Carcinoma after Excision for Biopsy-proven Tumor: Clinical and Medicolegal Implications
Plastic and Reconstructive Surgery, Global Open
title No Residual Basal Cell Carcinoma after Excision for Biopsy-proven Tumor: Clinical and Medicolegal Implications
title_full No Residual Basal Cell Carcinoma after Excision for Biopsy-proven Tumor: Clinical and Medicolegal Implications
title_fullStr No Residual Basal Cell Carcinoma after Excision for Biopsy-proven Tumor: Clinical and Medicolegal Implications
title_full_unstemmed No Residual Basal Cell Carcinoma after Excision for Biopsy-proven Tumor: Clinical and Medicolegal Implications
title_short No Residual Basal Cell Carcinoma after Excision for Biopsy-proven Tumor: Clinical and Medicolegal Implications
title_sort no residual basal cell carcinoma after excision for biopsy proven tumor clinical and medicolegal implications
url http://journals.lww.com/prsgo/Fulltext/2013/12000/Article.5.aspx
work_keys_str_mv AT raffigurunluoglumdphdfacs noresidualbasalcellcarcinomaafterexcisionforbiopsyproventumorclinicalandmedicolegalimplications
AT eddiekubekmd noresidualbasalcellcarcinomaafterexcisionforbiopsyproventumorclinicalandmedicolegalimplications
AT jamieartonpac noresidualbasalcellcarcinomaafterexcisionforbiopsyproventumorclinicalandmedicolegalimplications
AT adamolsendds noresidualbasalcellcarcinomaafterexcisionforbiopsyproventumorclinicalandmedicolegalimplications
AT michaelbronsertphdms noresidualbasalcellcarcinomaafterexcisionforbiopsyproventumorclinicalandmedicolegalimplications